iBio is expanding its capabilities and services to include the development and cGMP manufacturing of Fc fusion proteins for therapeutic pharmaceutical applications.   Fc fusion proteins are typically created using Chinese hamster ovary (CHO) cells and combining the active portion of a desirable protein with the naturally stable “tail portion” of an antibody protein. The resulting hybrid protein can exhibit important commercial and clinical advantages over both the original protein and tr...